Gujarat Kidney Super Speciality Ltd vs Vaidya Sane Ayurved Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 176.95 as of 23 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Vaidya Sane Ayurved Laboratories Ltd changed from 51.1 on March 2023 to 19.5 on March 2026 . This represents a CAGR of -21.40% over 4 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 247.07 crore on March 2023 to ₹ 175.15 crore on March 2026 . This represents a CAGR of -8.24% over 4 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Vaidya Sane Ayurved Laboratories Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Vaidya Sane Ayurved Laboratories Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 8 quarters. This represents a CAGR of 34.06% The net profit of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Vaidya Sane Ayurved Laboratories Ltd changed from 5.06 % on March 2023 to 0 % on March 2026 . This represents a CAGR of -100.00% over 4 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Vaidya Sane Ayurved Laboratories Ltd

Vaidya Sane Ayurved Laboratories Limited was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name Vaidya Sane Ayurved Laboratories Private Limited'.
Subsequently, Company was converted into to a Public Limited Company and the name of Company was changed to Vaidya Sane Ayurved Laboratories Limited'.
A fresh Certificate of Incorporation upon conversion was issued on November 25, 2021 by the Registrar of Companies, Pune. The Company is a unique medical service institution to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda.
Its approach to treatment using non-invasive, multidisciplinary and innovative therapies has helped the Company for treating the chronic ailments.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Vaidya Sane Ayurved Laboratories Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Vaidya Sane Ayurved Laboratories Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,395 Cr while Market cap of Vaidya Sane Ayurved Laboratories Ltd is 153 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Vaidya Sane Ayurved Laboratories Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Vaidya Sane Ayurved Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Vaidya Sane Ayurved Laboratories Ltd?

As of October 25, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹176.95. On the other hand, Vaidya Sane Ayurved Laboratories Ltd stock price is INR ₹146.45.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Vaidya Sane Ayurved Laboratories Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Vaidya Sane Ayurved Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.